查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701376

Herceptin市場規模、佔有率、趨勢分析報告：按產品、應用、付款人、分銷管道、地區、細分市場預測，2025-2030 年

Herceptin Market Size, Share & Trends Analysis Report By Product (Biosimilar, Biologic) By Application (Breast Cancer, Stomach/Gastric Cancer), By Payer (Commercial/Private, Public), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Herceptin市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，預計到2030年全球Herceptin市場規模將達到41億美元，2025年至2030年期間的複合年成長率為5.5%。

Herceptin市場的主要驅動力是其在治療 HER2 陽性癌症（尤其是乳癌和胃癌）方面的既定療效。Herceptin透過直接抑制 HER2 受體、抑制腫瘤生長和活化免疫介導的細胞毒性，徹底改變了治療模式。Herceptin被定位為早期和轉移性癌症的標準治療方法，支持其全球需求。Herceptin在聯合治療中發揮重要作用，尤其是與化療和較新的 HER2標靶藥物（聯合治療Pertuzumab使用，進一步增強了其治療相關性。隨著在新輔助和輔助治療中核准，Herceptin的患者基礎不斷擴大，現實世界的證據繼續支持Herceptin的長期生存益處。

然而，隨著美國（2019年）和歐洲（2014年）關鍵專利到期，Herceptin市場正在發生重大變化，帶來一波生物相似藥競爭。這種變化導致了嚴重的定價壓力，並降低了原創品牌產品的獨家經營權，尤其是在價格敏感的市場。對此，羅氏實施了生命週期管理策略，包括開發皮下（SC）製劑和Phesgo（SC）（Pertuzumab和曲妥珠單抗的固定劑量組合），以提高便利性、縮短給藥時間並維持患者忠誠度。這些創新不僅提高了醫療保健的效率，而且為生物相似藥在臨床實踐中提供了競爭優勢。

曲妥珠單抗生物相似藥市場強勁且快速擴張，輝瑞、安進、Biocon Biologics、三星 Bioepis 和 Celltrion 等多家公司已在全球市場獲得核准。曲妥珠單抗生物相似藥在高所得地區和新興地區的應用日益廣泛，這使得 HER2標靶治療的可及性變得更加民主，並顯著降低了治療成本。雖然這有利於醫療保健系統和患者，但也有可能侵蝕羅氏品牌Herceptin的市場佔有率。全球監管機構正在透過明確的可互換指南和獎勵採購模式支持生物相似藥的採用，進一步加速其採用。在印度、中國和拉丁美洲等地區，特定國家的生物相似藥數量正在增加，競爭日益激烈，尤其是在成本控制是優先考慮的地區。

儘管存在這些不利因素，Herceptin市場仍透過適應症擴展、策略合作和區域成長擁有巨大的機會。尤其是隨著醫療保健系統尋求更有效的給藥方式，SC Herceptin和 Phesgo 在門診和社區環境中的使用預計將會擴大。此外，將曲妥珠單抗與免疫查核點抑制劑（如Pembrolizumab）組合方案治療 HER2 陽性胃癌，為其應用開闢了新領域。這些新聯合治療目前正在臨床試驗中進行評估，可能會擴大Herceptin在傳統 HER2 陽性適應症之外的作用。此外，儘管由於生物相似藥的競爭導致單位價格下降，但中低收入國家意識的提高、篩檢率的上升以及診斷途徑的改善預計將推動銷售量成長。

展望未來，Herceptin市場可能會穩定在一個新的平衡狀態，即原始藥物和生物相似藥的共存成為常態。羅氏向增值產品和真實世界性能數據的策略轉變對於保持其市場地位至關重要。同時，生物相似藥製造商準備利用規模經濟、成本領先和區域夥伴關係來滲透服務不足的市場。此外，新的給藥創新和數位治療監測工具可能會增強曲妥珠單抗在不斷發展的治療模式中的效用。總體而言，雖然Herceptin在獨佔權或定價權方面可能不再佔上風，但它將繼續在 HER2 標靶癌症治療中發揮重要作用，特別是作為更廣泛的組合策略和綜合護理解決方案的一部分。

Herceptin市場報告重點

  • 從產品來看，隨著Herceptin在美國和歐洲的主要專利到期到期，在已開發市場和新興市場均被廣泛採用的生物相似藥將在2024年佔據Herceptin市場的主導地位，佔據50.93%的最大佔有率。多家製造商提供具有成本效益的曲妥珠單抗生物相似藥，顯著改善了 HER2標靶治療的可及性，特別是在癌症負擔高且醫療保健系統成本敏感的地區。有競爭力的定價、本地製造和支持性法律規範進一步刺激了生物相似藥的廣泛採用。相較之下，生物製藥/原始藥物（羅氏公司的Herceptin）領域佔據第二大市場佔有率，但由於其市場獨佔權和銷售量不斷輸給生物相似藥，其市場佔有率正在下降。
  • 根據應用情況，乳癌預計將在 2024 年佔據Herceptin市場的主導地位，佔有率為 57.68%，這得益於其作為 HER2 陽性乳癌的一線和輔助性治療的既定用途。該藥物在早期和轉移性乳癌中的長期作用，加上強力的臨床證據和指南支持，確保了持續的需求。由於 HER2 陽性胃癌和胃食道癌的核准擴大以及它們與查核點抑制劑（如Pembrolizumab）的聯合使用日益增多，預計預測期內胃癌/胃食道癌的複合年成長率將最快。
  • 根據付款人，私人/私人保險部門在 2024 年佔據最大的市場佔有率，為 91.03%，這得益於新興市場對品牌和生物學名藥曲妥珠單抗的廣泛報銷。 HER2標靶治療通常包含在綜合腫瘤福利計劃中。公共衛生領域預計將出現加速成長，特別是在新興經濟體，這些國家的國家衛生計畫正在擴大生物相似藥的使用範圍，將其作為原廠生技藥品的經濟有效的替代品。
  • 根據銷售管道，醫院藥局將繼續引領市場，2024 年的市場佔有率為 51.77%，這反映了癌症中心對輸液管理和監測的需求。Herceptin是一種輸液製劑，癌症治療方法的複雜性導致了醫院系統中給藥量的增加。由於Herceptin及其組合藥物Phesgo（曲妥珠單抗 +Pertuzumab）的皮下製劑在門診和居家醫療環境中得到越來越廣泛的應用，為患者提供了更大的靈活性和便利性，預計專業藥房的複合年成長率將最快。
  • 2024年4月，FDA加速核准Enhertu（fam-trastuzumab deruxtecan-nxki），用於治療先前全身性治療後病情進展的不可切除或轉移性HER2陽性固體癌患者。這是HER2標靶治療首次核准作為腫瘤診斷劑，將用途擴展到乳癌和胃癌等傳統適應症之外。這項核准是基於 DESTINY-PanTumor02 試驗的結果，該研究表明 ENHERTZ 對多種癌症表現出顯著的反應率，包括膽道癌、膀胱癌和子宮內膜癌。這項發展顯著擴展了 HER2標靶治療的臨床效用，並使 Enhertu 成為不斷發展的精準腫瘤學領域的主要參與者。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章Herceptin市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場成長要素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 專利到期分析
    • 定價和報銷方案
    • 併購與交易
    • 學名藥/生物相似藥的影響

第4章Herceptin市場：按產品分類的業務分析

  • 2024年及2030年的產品市場佔有率
  • 產品細分儀表板
  • 市場規模、預測與趨勢分析（按產品，2018-2030 年）
  • 生物製藥
  • 生物相似藥

第5章Herceptin市場：按應用進行的業務分析

  • 2024 年和 2030 年應用市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2018-2030 年）
  • 乳癌
  • 胃癌

第6章Herceptin市場：按付款者進行的業務分析

  • 2024 年及 2030 年付款人市場佔有率
  • 付款人細分儀表板
  • 付款人的市場規模、預測和趨勢分析（2018-2030）
  • 商業/個人
  • 公共

第7章Herceptin市場：按分銷管道進行的業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 專業藥房

第8章Herceptin市場：區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模與預測趨勢分析：
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章競爭格局

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/列表
    • Roche Holding AG（Genentech）
    • Pfizer Inc.
    • Samsung Bioepis Co., Ltd.
    • Amgen Inc.
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Mylan NV（Viatris）
    • Prestige Biopharma
    • Shanghai Henlius Biotech, Inc.
    • AryoGen Pharmed
    • Dr. Reddy's Laboratories
Product Code: GVR-4-68040-540-6

Herceptin Market Growth & Trends:

The global herceptin market size is anticipated to reach USD 4.10 billion by 2030 and is projected to grow at a CAGR of 5.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key driver of the Herceptin market is its established efficacy in treating HER2-positive cancers, particularly breast and gastric cancers. As one of the earliest and most successful targeted therapies, Herceptin revolutionized the treatment paradigm by directly inhibiting the HER2 receptor, halting tumor growth, and activating immune-mediated cytotoxicity. Its inclusion as a standard-of-care therapy in both early-stage and metastatic settings continues to anchor its global demand. Herceptin's role in combination regimens-especially with chemotherapy and newer HER2-targeted agents like pertuzumab-further boosts its therapeutic relevance. Approvals in neoadjuvant and adjuvant contexts have expanded its patient base, while real-world evidence continues to support its long-term survival benefits.

However, Herceptin's market has undergone significant transformation due to the expiration of key patents-in the U.S. (2019) and Europe (2014)-which has opened the door to a wave of biosimilar competition. This shift has led to intense pricing pressures and reduced exclusivity for the originator product, especially in price-sensitive markets. In response, Roche has implemented lifecycle management strategies, including the development of a subcutaneous (SC) formulation and the co-formulated fixed-dose combination Phesgo (pertuzumab + trastuzumab SC), aimed at improving convenience, reducing administration time, and maintaining patient loyalty. These innovations not only enhance healthcare efficiency but also offer a competitive edge against biosimilars in clinical practice.

The biosimilar landscape for trastuzumab is robust and rapidly expanding, with multiple players such as Pfizer, Amgen, Biocon Biologics, Samsung Bioepis, and Celltrion securing approvals across global markets. The growing adoption of trastuzumab biosimilars in both high-income and emerging regions has democratized access to HER2-targeted therapy, significantly lowering treatment costs. While this benefits healthcare systems and patients, it also presents market share erosion risks for Roche's branded Herceptin. Regulatory authorities worldwide have supported biosimilar adoption through clear interchangeability guidelines and incentivized procurement models, further accelerating their uptake. The increasing number of country-specific biosimilars in regions like India, China, and Latin America is intensifying competition, especially where cost containment is a priority.

Despite these headwinds, opportunities remain strong in the Herceptin market through expanding indications, strategic partnerships, and regional growth. The uptake of SC Herceptin and Phesgo in outpatient and community settings is poised to grow, particularly as healthcare systems seek more efficient delivery options. Additionally, the inclusion of trastuzumab in combination regimens with immune checkpoint inhibitors, such as pembrolizumab in HER2-positive gastric cancer, is opening new frontiers for its use. These novel combinations are being evaluated in clinical trials and could expand Herceptin's role beyond traditional HER2-positive indications. Furthermore, rising awareness, increasing screening rates, and improving access to diagnostics in low-to-middle-income countries are expected to fuel volume growth, even if unit prices decline due to biosimilar competition.

Looking ahead, the Herceptin market will likely stabilize at a new equilibrium, where originator and biosimilar coexistence is the norm. Roche's strategic pivot toward value-added products and real-world outcomes data will be critical in retaining market presence. Meanwhile, biosimilar manufacturers are poised to benefit from scale, cost leadership, and local partnerships, which will help them penetrate underserved markets. Emerging delivery innovations and digital treatment monitoring tools may also enhance trastuzumab's utility in evolving care models. Overall, while Herceptin may no longer dominate in terms of exclusivity or pricing power, it will continue to play a pivotal role in HER2-targeted oncology, especially as part of broader combination strategies and integrated care solutions.

Herceptin Market Report Highlights:

  • Based on product, biosimilars dominated the Herceptin market in 2024, accounting for the largest share of 50.93%, driven by widespread adoption across both developed and emerging markets following the expiration of Herceptin's key patents in the U.S. and Europe. The availability of cost-effective trastuzumab biosimilars from multiple manufacturers has significantly improved access to HER2-targeted therapy, especially in regions with high cancer burden and cost-sensitive healthcare systems. Competitive pricing, local manufacturing, and supportive regulatory frameworks have further fueled biosimilar uptake. In contrast, the biologic/originator segment (Roche's Herceptin) holds the second-largest share but is witnessing a declining trend, as it continues to lose market exclusivity and volume to biosimilars.
  • Based on application, breast cancer dominated the Herceptin market in 2024 with a share of 57.68%, driven by its established use as a first-line and adjuvant therapy in HER2-positive breast cancer. The drug's long-standing role in both early-stage and metastatic breast cancer, combined with strong clinical evidence and guideline support, has ensured continued demand. Stomach/gastric cancer is projected to grow at the fastest CAGR over the forecast period, supported by expanded approvals for HER2-positive gastric and gastroesophageal cancers and growing use in combination with checkpoint inhibitors like pembrolizumab.
  • Based on payer, the commercial/private insurance segment accounted for the largest share at 91.03% in 2024, due to broad reimbursement for branded and biosimilar trastuzumab across developed markets. Access to HER2-targeted therapy is typically covered under comprehensive oncology benefit plans. The public insurance segment is expected to experience faster growth, particularly in emerging economies where national health programs are expanding access to biosimilars as cost-effective alternatives to originator biologics.
  • Based on distribution channel, hospital pharmacies remained the leading segment with a 51.77% market share in 2024, reflecting the need for infusion-based administration and monitoring within oncology centers. Herceptin's IV formulation and the complexity of oncology regimens reinforce its delivery through hospital-based systems. Specialty pharmacies are projected to register the fastest CAGR, as the subcutaneous formulation of Herceptin and the combination product Phesgo (trastuzumab + pertuzumab) become more widely adopted in outpatient and home-care settings, offering greater flexibility and improved patient convenience.
  • In April 2024, the FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive solid tumors that are unresectable or metastatic and have progressed following prior systemic treatment. This marks the first tumor-agnostic approval for a HER2-targeted therapy, expanding its use beyond traditional indications like breast and gastric cancers. The approval was based on results from the DESTINY-PanTumor02 trial, where Enhertu demonstrated meaningful response rates across multiple cancer types, including biliary tract, bladder, and endometrial cancers. This development significantly broadens the clinical utility of HER2-targeted therapies and positions Enhertu as a major player in the evolving landscape of precision oncology.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Payer
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Herceptin Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Patent Expiry Analysis
    • 3.3.4. Pricing and Reimbursement Scenario
    • 3.3.5. M&A and Deals
    • 3.3.6. Impact of Generics/Biosimilars

Chapter 4. Herceptin Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Biologic
    • 4.4.1. Biologic Market, 2018 - 2030 (USD Million)
  • 4.5. Biosimilar
    • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Herceptin Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Breast Cancer
    • 5.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
  • 5.5. Stomach/Gastric Cancer
    • 5.5.1. Stomach/Gastric Cancer Market, 2018 - 2030 (USD Million)

Chapter 6. Herceptin Market: Payer Business Analysis

  • 6.1. Payer Market Share, 2024 & 2030
  • 6.2. Payer Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Payer, 2018 to 2030 (USD Million)
  • 6.4. Commercial/Private
    • 6.4.1. Commercial/Private Market, 2018 - 2030 (USD Million)
  • 6.5. Public
    • 6.5.1. Public Market, 2018 - 2030 (USD Million)

Chapter 7. Herceptin Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Pharmacy
    • 7.5.1. Specialty Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8. Herceptin Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Herceptin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Herceptin Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Roche Holding AG (Genentech)
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Samsung Bioepis Co., Ltd.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Amgen Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Celltrion Healthcare Co., Ltd.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Biocon Limited
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Mylan N.V. (Viatris)
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Prestige Biopharma
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Shanghai Henlius Biotech, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. AryoGen Pharmed
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Dr. Reddy's Laboratories
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Herceptin market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 6 Global Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 7 Global Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 10 North America Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 12 North America Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 14 U.S. Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16 U.S. Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 18 Canada Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 20 Canada Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 22 Mexico Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 24 Mexico Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 27 Europe Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29 Europe Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 31 UK Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 33 UK Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 35 Germany Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 37 Germany Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 39 France Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 40 France Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41 France Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 43 Italy Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 45 Italy Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 47 Spain Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 49 Spain Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Norway Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 51 Norway Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 52 Norway Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 53 Norway Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Denmark Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 55 Denmark Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57 Denmark Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Sweden Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 59 Sweden Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 60 Sweden Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 61 Sweden Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Japan Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 68 Japan Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 70 Japan Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 China Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 72 China Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 73 China Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 74 China Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 76 India Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 77 India Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 78 India Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 80 Australia Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 82 Australia Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 84 South Korea Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86 South Korea Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 88 Thailand Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 90 Thailand Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 93 Latin America Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95 Latin America Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Brazil Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 97 Brazil Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 98 Brazil Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 99 Brazil Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 101 Argentina Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 102 Argentina Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 103 Argentina Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 South Africa Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 110 South Africa Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 111 South Africa Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 112 South Africa Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117 UAE Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 118 UAE Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 119 UAE Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 120 UAE Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Herceptin market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Herceptin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Herceptin market dynamics
  • Fig. 12 Herceptin market: Porter's five forces analysis
  • Fig. 13 Herceptin market: PESTLE analysis
  • Fig. 14 Herceptin market by product product (USD Million)
  • Fig. 15 Biologic product revenue trend in Herceptin market (USD Million)
  • Fig. 16 Biosimilar product market share analysis (USD Million)
  • Fig. 17 Herceptin market application segmentation (USD Million)
  • Fig. 18 Breast cancer treatment revenue share in Herceptin market (USD Million)
  • Fig. 19 Gastric cancer Herceptin usage trend and forecast (USD Million)
  • Fig. 20 Herceptin market by payer product (USD Million)
  • Fig. 21 Commercial/private insurance coverage and adoption trend (USD Million)
  • Fig. 22 Public insurance reimbursement growth in Herceptin market (USD Million)
  • Fig. 23 Herceptin distribution channel market share (USD Million)
  • Fig. 24 Hospital pharmacy distribution analysis for Herceptin (USD Million)
  • Fig. 25 Specialty pharmacy Herceptin delivery growth trend (USD Million)
  • Fig. 26 Herceptin market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia-Pacific Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East & Africa (MEA) Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework